We have created a marketplace for precision medicine tools and services that connect customers in pharma or life sciences research with innovative solutions.
The problem pharma currently faces is that 90% of all investment goes into programs what ultimately do not bear fruit. The problem for patients is that only 10% of cancer patients are eligible for gene-informed therapy, only these treatments only work half of the time.
With our solutions pharma and researchers can reproduce human physiology in a dish, and patients can test treatments outside of the body. Pharma can use these tools to reduce development time by more than half and cost by more than three quarters.
This B2B market is growing at 25% CAGR. Flowcell will capitalize on this timely opportunity, and also to address $1T TAM market by becoming The precision medicine marketplace and address the needs for individualized healthcare that impacts 10% of global GDP.
In the short term, we make money by selling consultancy service for technologies, modeling of microfluidics, software and analytics.
Medium and long term we monetize our marketplace through sponsored services and commission basis: connecting providers in precision oncology with hospitals and patients.
The main revenue driver is distribution of consumables for innovative tools with 15-30% commission. We are connected to The professional association advancing this field in USA and have distribution and marketing agreements with over a dozen cutting edge providers, with expectations of over 50 by the end of the year.
We plan to acquire customers primarily through the FluidsForLife.com marketplace, which has very little competition from ScienceExchange.com, Scientist.com, Darwin- and Dolomite Microfluidics.
Our core team of 8 includes seasoned CXOs and over a dozen part-time associates.
We are raising $3M Seed, which will enable use to reach $14M in sales and in two years and over $200 in six years.
Ready to Ask For Funding for your company?
Post a Funding Request